Developer of small-molecule antiviral therapeutics designed to treat hepatitis C virus (HCV) infection. The company's antiviral therapeutics offer once-daily oral dosing and can be combined with other classes of HCV antivirals to combat viral resistance, enabling patients to access effective drug therapies against a variety of known HCV genotypes.
The company raised $21.83 million of Series D venture funding from Crown Predator Holdings, Five Corners Capital and other undisclosed investors on June 13, 2014, putting the pre-money valuation at $15 million.
Most visits will take between 1.5 and 2 hours. The agenda for a specific visit depends on your group, its interests and objectives as well as on the host company. A visit may include a company or industry specific presentation, a discussion around a specific product or service, partnership opportunities, a demo, a meeting of the premises, etc.